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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen
worldwide. The need for accurate and rapid screening methods to detect MRSA carriers has been
clearly established. The performance of a novel assay, BacLite Rapid MRSA (Acolyte Biomedica, UK)
for the rapid detection (5 h) and identification of hospital associated ciprofloxacin resistant strains
of MRSA directly from nasal swab specimens was compared to that obtained by culture on Mannitol
salt agar containing Oxacillin (MSAO) after 48 h incubation.
Results: A total of 1382 nasal screening swabs were tested by multiple operators. The BacLite
Rapid MRSA test detected 142 out of the 157 confirmed MRSA that were detected on MSAO giving
a diagnostic sensitivity of 90.4, diagnostic specificity of 95.7% and a negative predictive value of
98.7%. Of the 15 false negatives obtained by the BacLite Rapid MRSA test, seven grew small
amounts (< 10 colonies of MRSA) on the MSAO culture plate and five isolates were ciprofloxacin
sensitive. However there were 13 confirmed BacLite MRSA positive samples, which were negative
by the direct culture method, probably due to overgrowth on the MSAO plate. There were 53 false
positive results obtained by the BacLite Rapid MRSA test at 5 h and 115 cases where MRSA
colonies were tentatively identified on the MSAO plate when read at 48 h, and which subsequently
proved not to be MRSA.
Conclusion: The Baclite MRSA test is easy to use and provides a similar level of sensitivity to
conventional culture for the detection of nasal carriage of MRSA with the advantage that the results
are obtained much more rapidly.
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Background
The use of screening cultures to identify MRSA-colonised
patients so that infection control measures can be imple-
mented and prevent transmission to other patients, is well
established [1]. Recent guidelines from the Society for
Healthcare Epidemiology of America emphasize the
importance of identifying reservoirs of nosocomial trans-
mission by use of active screening methods [2]. However,
traditional methods used to screen for MRSA rely on
labour intensive and time consuming culture techniques
which do not exclude MRSA for 48 h and may require a
further 1–2 days to confirm positives [3]. The use of chro-
mogenic media may reduce the time significantly, but
there are few published studies on their efficacy [3]. Dur-
ing this time period, infection control measures, such as
isolation, or cohorting of patients and prophylactic
decontamination may be applied unnecessarily, or if not
applied, unidentified MRSA-positive individuals may
remain a hidden reservoir for cross infection. A rapid neg-
ative result should allow more effective use of hospital
isolation resources, whilst a rapid positive result should
help reduce the spread of the infection and MRSA infec-
tion rates
In recent years a variety of increasingly sophisticated
DNA-based tests have been developed to detect MRSA car-
riage more rapidly [4,5]. Most of these assays are based on
the detection of an S. aureus-specific sequence and the
mecA gene, which encodes methicillin resistance, with a
variety of methods to differentiate MRSA from methicillin
resistant coagulase negative staphylococci which may also
be present [6]. Despite the technical improvements in
molecular based assays, their high cost and relatively high
operator skill requirement remain obstacles to their wide-
spread routine use.
This study describes the evaluation of the BacLite MRSA, a
rapid culture based test which has been developed to
detect ciprofloxacin resistant MRSA strains that have been
associated with hospital acquired infections within the
UK. The test measures Adenylate Kinase (AK) activity.
Adenylate kinase (AK), is an essential 'house keeping'
enzyme found inside all cells which regulates energy pro-
vision by catalysing the equilibrium reaction: ATP + AMP
↔ 2ADP. By supplying purified ADP in vitro, the reaction
can be driven to generate up to 40,000 ATP molecules per
minute. The amplified levels of ATP produced during a
typical 5 minute reaction period can then be measured
using the bioluminescent reaction of firefly luciferase. In
this BacLite MRSA assay, AK detection is combined with
selective broth enrichment, magnetic microparticle extrac-
tion and selective lysis of S. aureus to add target organism
specificity. In the extraction step, paramagnetic micro-par-
ticles coupled with a mouse anti-Staphylococcus aureus
monoclonal antibody are used to capture MRSA. The
unbound fraction is removed by washing. Capture and
washing occur as automated steps inside the automated
wash module. In the lysis step, a reagent containing lys-
ostaphin and ADP is added and the S. aureus in the sample
lysed to release adenylate kinase (AK). The AK then catal-
yses conversion of ADP to ATP. Firefly luciferin and luci-
ferase are added and light is emitted in the presence of
ATP [7].
Results
A total of 1382 nasal screening swabs were tested by mul-
tiple operators and the results are shown in the table. The
BacLite Rapid MRSA test detected 142 out of the 157 con-
firmed MRSA that were detected on MSAO giving a diag-
nostic sensitivity of 90.4 and a diagnostic specificity of
95.7% (Table). This gives a negative predictive value of
98.7%. Of the 15 false negatives obtained by the BacLite
Rapid MRSA test, seven grew small amounts (< 10 colo-
nies of MRSA) on the MSA culture plate and five isolates
were ciprofloxacin sensitive.
There were 53 false positive results obtained by the
BacLite Rapid MRSA test of which approximately 70%
were due to the presence of methicillin resistant coagulase
negative staphylococci (MRCNS). There were 115 cases
where suspect MRSA colonies were tentatively identified
on the MSAO agar when read at 48 h, subcultured for fur-
ther identification and subsequently proved not to be
MRSA.
There were 13 confirmed BacLite MRSA positive samples
which were negative by the reference method. In all these
cases MRSA was isolated when the enriched BacLite broth
was subcultured onto MSAO. In all cases MRSA was iso-
lated, although in one case a non mannitol fermenting
strain of MRSA was isolated There is no obvious explana-
tion for the remaining 12 cases but in six of them the
MSAO plates from the direct plating were recorded as
being overgrown with commensal organisms which may
have masked the presence of MRSA. The other cases may
be due to the superior sensitivity of a broth enrichment
method for the recovery of low numbers of organisms or
have arisen simply by chance.
Discussion
Laboratory screening for MRSA is a complex balance
between turn around time, performance (sensitivity, spe-
cificity), ease of use, and cost. The majority of MRSA
screening is carried out in clinical microbiology laborato-
ries using plate based culture methods with or without
prior broth enrichment. Broth based enrichment media
enhance test sensitivity but adds an extra day to testing,
and in any case the significance of the increased sensitiv-
ity, which is presumably due to increased recovery of low
numbers of MRSA is not clear [3]. Direct plating ontoBMC Microbiology 2006, 6:83 http://www.biomedcentral.com/1471-2180/6/83
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solid media is therefore the most commonly used screen-
ing approach. There is no one solid medium that is clearly
superior to any other for screening. MSAO is widely used
as a screening medium both nationally and internation-
ally and is one of two culture media (the other being cip-
rofloxacin containing Baird Parker medium) in the UK
Health Protection Agency's national standard operating
procedures, and was used in this study for comparison [3].
One major disadvantage of using MSAO is the growth of
a large number of suspect colonies which require further
testing and which are subsequently shown not to be
MRSA. There is considerable individual variation between
operators in the number of colonies which are tested. In
this study, performed by several different operators, 115
out of 254 colonies which were sub cultured for further
testing, were shown not to be MRSA, representing a sub-
stantial waste of resources. In comparison, there were 53
presumptive positives obtained by the BacLite Rapid
MRSA which significantly reduces the number of follow
up tests typically required by conventional methods.
The results of the study include 5 ciprofloxacin-sensitive
(MIC = ≤ 6 mg/l) MRSA samples identified by the MSAO
culture method which the BacLite assay did not detect, as
it has been developed to detect the predominantly cipro-
floxacin resistant MRSA strains that have been associated
with hospital acquired infections within the UK. Cipro-
floxacin containing media is widely used in the UK and
although ciprofloxacin susceptible organisms will be
missed the isolation rate with these media has been
reported to be higher than other routinely used plate
media like MSAO [3]. Of the 10 remaining false negative
samples reported by the BacLite Rapid MRSA test, seven
grew small amounts (< 10 colonies of MRSA) on the
MSAO culture plate. It is possible that all culturable MRSA
may have been removed from the swab when inoculating
the MSAO plate prior to testing in the BacLite assay, or
antibiotic treatment may have impacted on MRSA cultur-
ability increasing lag times or reducing organism growth
rates.
Rapid identification or exclusion of MRSA colonization is
increasingly seen as essential for the effective control of
MRSA and other antibiotic resistant organisms in the hos-
pital environment prompting the development of rapid
tests for the detection of MRSA.
To reduce the time taken for this evaluation, wards were
selected which had previously reported MRSA in the last 3
months, thus increasing the apparent prevalence of MRSA
in the hospitals. This does not significantly affect the NPV
but would have biased the positive predictive value[8].
For this reason, the latter is not shown. The high NPV of
the BacLite Rapid MRSA (98.7%) test allows negative
results to be confidently reported in 5 h. As negative sam-
ples make up the vast majority of MRSA screening tests
this represents a significant benefit to laboratories. A use-
ful feature of the assay is that it has been designed to retain
a sample of the broth containing enriched MRSA from
which to perform direct sensitivity tests and confirm pre-
sumptive positive results.
There were 13 confirmed BacLite MRSA positive samples
which were negative by the reference culture method.
Although they were classed as 'false positives' as the results
were different from those of the reference method, they
cannot be considered as false positives in the usual sense
of the term, as a viable MRSA was isolated from the
enriched Baclite broth. The better performance of the
BacLite test in these samples was largely due to over-
growth of commensal organisms on the selective manni-
tol salt agar masking the presence of MRSA and, in one
case the presence of a non mannitol fermenting strain of
MRSA.
The material costs of the Baclite test are of the order of £5-
6 per test, which is higher than a culture based method,
but much lower than commercial molecular based tests.
The Baclite test was only evaluated in this study with nasal
swabs, although similar results have been obtained from
other body sites with screening swabs (Johnson Millar,
Wilks, unpublished results). The Baclite test requires a rel-
atively low level of expertise and can be performed by a
trained laboratory assistant, whereas the skill mix
required to operate a PCR system may not be readily avail-
able in the diagnostic laboratory.
A full cost benefit analysis was beyond the scope of this
study. Such an analysis is extremely complex because it
must take into account not only the costs and perform-
ance of the test in the laboratory, but arguably more
important, how a rapid MRSA test is integrated into the
workings of the laboratory and the hospital, which is dif-
ficult to quantify. In addition the benefits of a rapid test
Table 1: Comparison of the BacLite Rapid MRSA test results with those obtained by the reference method
BacLite MRSA positive BacLite MRSA negative Total
Reference method: MSAO culture and confirmatory tests Positive 142 15 157
Negative 53 1172 1225
Total 195 1187 1382BMC Microbiology 2006, 6:83 http://www.biomedcentral.com/1471-2180/6/83
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like the BacLite test or PCR, are dependent on factors
which may not be under the laboratory control. For exam-
ple the benefits of any time savings could be negated with-
out an efficient specimen transport system in place, and
an efficient method of reporting the results. An important
consideration is the effect that a result obtained in about
5 h may have on the action taken by infection control
staff. Specimens arriving for testing in the afternoon by
the Baclite method may not be processed in time for infec-
tion control procedures to be implemented by the end of
the day. Thus, action could not be taken until the follow-
ing morning at the earliest. At present, because of the
slowness of conventional culture methods and the short-
ening times of inpatient length of stay, action may not be
taken on confirmed positive results, before the patient has
been discharged. With a rapid test system, infection con-
trol facilities such as the number of isolation beds, may
have to be increased to take into account the more rapid
reporting of results.
Conclusion
We describe here the first example of a rapid non molecu-
lar MRSA screening test.
The BacLite Rapid MRSA test is a sensitive and specific test
for the detection of ciprofloxacin resistant MRSA nasal
colonisation directly from a swab. The assay retains many
of the advantages of traditional broth based methods but
can provide an MRSA screening test result direct from a
clinical swab within 5 hours. The test is easy to use and
provides an alternative to conventional culture, or molec-
ular approaches, for the detection of viable MRSA in rou-
tine clinical microbiology laboratories.
Methods
Clinical samples
From April to May 2005, the BacLite Rapid MRSA assay
was evaluated by testing 1382 nasal screening swabs (cot-
ton swabs with non-charcoal Amies transport medium,
Medical Wire & Equipment, Wilts) from in-patients at 3
different hospitals within the United Kingdom. All swabs
were taken as part of routine screening for MRSA coloni-
sation according to local hospital infection control poli-
cies and anonymised according to local ethics committee
requirements. To increase the sample positivity rate,
wards were selected which had reported the presence of
MRSA in the past 6 months. All specimens were trans-
ported and stored at room temperature and tested within
48 hours of sampling.
Culture methods
All swabs samples were first spread on mannitol salt agar
plates containing sodium chloride (5%) and oxacillin (4
mg/l) (MSAO agar, E & O Laboratories, Scotland) before
processing by the Baclite method. After incubation at
37°C for 48 hours, the presence of mannitol-fermenting
colonies with a staphylococcal morphology was recorded
as a presumptive positive result.
MSAO plate culture presumptive positive isolates and the
broth from BacLite presumptive positive samples were
sub cultured onto horse blood agar, incubated overnight
and colonies resembling S. aureus tested to confirm their
identification by standard microbiology techniques (latex
agglutination, deoxyribonuclease agar, tube coagulase).
Methicillin resistance was confirmed by testing pure iso-
lates for sensitivity to methicillin by UK standardized disc
susceptibility methods [9].
BacLite Rapid method
All specimens were processed according to the manufac-
turers instructions provided with the product. MSAO
plates were inoculated first followed by the BacLite Rapid
MRSA assay within 2 hours to avoid any bias due to
processing delays. Positive and negative control strains
(MRSA, MSSA) were included as procedural controls in
each run. Swab samples were vortexed in the proprietary
selective broth (containing ciprofloxacin (6 mg/l) for 2 ×
5 sec and incubated at 37°C for 2.5 h. MRSA were cap-
tured and washed in the BacLite sample processor. The
bound fraction was re-suspended in the selective broth
and aliquots of each sample were placed into two adjacent
wells of a 96 well assay plate (Corning Incorporated, NY).
One well for each sample was used to determine a base-
line signal (T0) in the BacLite reader. After a further incu-
bation period of 2 hours at 37°C, the second well for each
sample was processed in the same way (T2 reading). The
result was determined by subtracting the T2 from the T0
reading and scored automatically as positive or negative
according to a software embedded algorithm. Baclite
assay-positive results were recorded as a presumptive pos-
itive and a sample of the incubated selective broth subcul-
tured for confirmatory testing onto MSAO agar.
In addition, when a sample gave an MSAO presumptive
positive reading (by colony morphology and presence of
mannitol fermentation), but had given a BacLite negative
reading, a ciprofloxacin susceptibility test was also carried
out by standard methods [9].
Quality controls
Reagent controls; 2 reagent controls were run with the
assay, the non-inoculated broth control and the AK con-
trol. The broth control was assayed to detect contamina-
tion. The AK control was a monitor of bioluminescent
reagent failure. An invalid result for either control invali-
dated the run.
Positive and negative controls were assayed with each run.
The positive control (EMRSA 16, supplied by Acolyte Bio-Publish with BioMed Central    and   every 
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medica) monitored failure of the assay run. The negative
control (Methicillin sensitive S. aureus strain NCTC 6571)
was a procedural control and also monitored for any con-
tamination of the assay. An incorrect result for either of
these invalidated the run.
Data analysis
Results from the BacLite Rapid MRSA assay were compared
to those obtained after 48 h incubation of swabs inocu-
lated onto MSAO agar. The total number of confirmed
MRSA-positive samples obtained from MSAO plate was
taken as the reference method in this study. Sensitivity,
susceptibility, and negative predictive value (NPV) were
calculated.
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